NICE announces start of review of nusinersen Managed Access Agreement

NICE has today (29 October 2020) announced that it has begun the process to review data collected as part of the Managed Access Agreement (MAA) for nusinersen (also called Spinraza and made by Biogen) for treating the rare genetic disorder spinal muscular atrophy (SMA).

Read news story



NICE Annual Conference

13 May 2021, Hilton Manchester Deansgate

Due to the ongoing COVID-19 pandemic, we have decided to postpone our annual conference from November 2020 until May 2021.

For further information, please visit the conference website.

Press and media

Contact the press office: 0300 323 0142 |